Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

durvalumab 7Gemcitabine 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Leucovorin 6Cisplatin 6Specimen Handling 5Fluorouracil 5Biopsy 5Paclitaxel 4Folfox protocol 4Irinotecan 3pemigatinib 2pembrolizumab 2olaparib 2futibatinib 2fludarabine 2dehydroftorafur 2Taxes 2Nivolumab 2Immunoglobulin G 2Fluorodeoxyglucose F18 2Disulfides 2Carboplatin 2zimberelimab 1zanidatamab 1ulixertinib 1tremelimumab 1trametinib 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × pevonedistat × 30 days × Clear all
NCT04175912 2026-05-29

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled 11 charts
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡